News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 26, 2015, 17:11 ET

Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

Janssen Research & Development, LLC announced today data from the multicenter, two-part, open-label Phase 1/2 GEN501 study published in The New...

Aug 12, 2015, 03:05 ET

Johnson & Johnson Innovation Announces Collaboration on Immuno-Oncology Antibody ADC-1013 with Alligator Bioscience

Janssen Biotech, Inc. (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide...

Jul 23, 2015, 17:43 ET
Janssen Logo.

Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application...

Jul 13, 2015, 04:31 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

IMBRUVICA®▼(ibrutinib) de Janssen reçoit une autre approbation donnée par la Commission européenne pour le traitement de la macroglobulinémie de Waldenström

Ce communiqué de presse a été rédigé en Anglais. Des traductions en Allemand, Français et Espagnol sont fournies...

Jul 13, 2015, 04:30 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssens IMBRUVICA®▼(Ibrutinib) erhält zusätzliche Zulassung der EU-Kommission für die Behandlung von Waldenströms Makroglobulinämie

Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire...

Jul 10, 2015, 11:54 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

IMBRUVICA®▼ de Janssen aprobado para el tratamiento de la macroglobulinemia de Waldenström

  Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán,...

Jul 08, 2015, 17:00 ET

Phase 2b Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis

 Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase...

Jul 08, 2015, 08:00 ET

CELLSEARCH® System chosen as platform for new research on PD-L1 and Circulating Tumor Cells

Janssen Diagnostics today announced that its CELLSEARCH® System technology was used in new research demonstrating the ability to detect...

Jul 06, 2015, 08:20 ET

Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma

 Janssen Biotech, Inc. (Janssen) announced today the opening of a daratumumab expanded access program (EAP) for eligible U.S. patients....

Jun 25, 2015, 08:57 ET

INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available

The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in...

Jun 06, 2015, 10:00 ET

New Data Show Initial Use of Canagliflozin in Combination with Metformin Extended Release Significantly Improves A1C Levels in Adults with Type 2 Diabetes

 Janssen Research & Development, LLC (Janssen) today announced results of a phase 3, randomized study showing that the use of initial...

Jun 05, 2015, 11:50 ET

Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma

Janssen Research & Development, LLC (Janssen) has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to...

Jun 03, 2015, 08:07 ET
Television and film actress Megan Park announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly disclosed living with a chronic autoimmune disease. Park made the announcement in partnership with Joint Decisions.

Actress Megan Park Shares Private Struggle With Rheumatoid Arthritis For The First Time Through "Joint Decisions" Educational Program

 Television and film actress Megan Park today announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly...

Jun 01, 2015, 17:00 ET

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant...

Jun 01, 2015, 16:22 ET
Jun 01, 2015, 12:04 ET
May 30, 2015, 07:32 ET

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

 Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA®) plus bendamustine and rituximab...

May 30, 2015, 07:31 ET

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

 Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent...

May 28, 2015, 08:30 ET

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

 Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new...